tbuckley/cabot-search huggingface dataset:
Long-term survival outcomes following resection of lung metastases (LM) from a colorectal primary.
Authors: Sangeetha Ramanujam, Catherine Dunn, Phillip Antippa, Suzanne Kosmider, Yat Hang To, Margaret Lee, Vanessa Wong, Susan Caird, Jeremy David Shapiro, Joseph James McKendrick, Hui-Li Wong, Brigette Ma, Stephanie Hui-Su Lim, Javier Torres, Allan Solomon Zimet, Belinda Lee, Peter Gibbs
Journal: Journal of Clinical Oncology (2022)

50 Background: Liver metastatectomy in oligometastatic colorectal cancer (CRC) can result in long-term disease control 1 . The benefit of resecting LM is unclear, with good survival outcomes from medical therapy (MT) alone and a recent randomised controlled trial failed to demonstrate an overall survival (OS) benefit 2 . Methods: We examined TRACC (Treatment of Recurrent and Advanced Colorectal Cancer), a multisite registry for metastatic colorectal cancer (mCRC) patients (pts) from September 2002 – July 2021, focusing on the longer-term outcomes for pts with lung only metastatic disease (LOM). Key clinicopathological, treatment and outcome variables were analysed. Survival outcomes were determined by Kaplan-Meier method. Results: Of 3928 pts, 341 (8.7%) had LOM. The median OS was significantly improved for LOM vs. all mCRC pts (44.5 months vs. 24.8 months, p = &lt;0.0001). Of 341 LOM pts, 142 (42%) had lung resection (LRes),128 (38%) had MT, 71 (20%) best supportive care. Key clinicopathological characteristics are summarised in Table. OS was significantly longer for LRes vs. MT (3yrs-80.1% vs. 41.9%, p = &lt;0.0001, 5 yrs-65.2% vs. 21.1%, p = 0.0001). 10 yr survival for LRes was 50%, with no survivors from MT. The median palliative chemotherapy free interval was 13 months (95% CI 3.1 – 18.7) with recurrence after LRes/death. 20/142 (14%) of the LRes pts had recurrent LRes (median time to repeat resection of 11.4 months, median survival of 66.9 months from repeat LRes). Conclusions: LM from mCRC have an indolent course, with good survival outcomes with MT alone. LRes provides a clinically meaningful palliative chemotherapy free interval and long term survival in selected pts. Significant differences in prognostic factors may have contributed to the observed survival differences between LRes and MT. Reference Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lehi Y, Tianshu L, Jia f, Xinyu Q, Jianmin X. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol. 2012 Sep;19(9):2860-8. doi:10.1245/s10434-012-2356-9.Epub 2012 Apr 12. PMID: 22526903. Treasure, T., Farewell, V., Macbeth, F. et al. Pulmonary Metastatectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials 20,718 (2019). https://doi.org/10.1186/s13063-019-3837-y [Table: see text]
Inverting the model of genomics data sharing with the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space
Authors: Michael C. Schatz, Anthony A. Philippakis, Enis Afgan, Eric Banks, Vincent J. Carey, Robert J. Carroll, Alessandro Culotti, Kyle Ellrott, Jeremy Goecks, Robert L. Grossman, Ira M. Hall, Kasper D. Hansen, Jonathan Lawson, Jeffrey T. Leek, Anne O’Donnell Luria, Stephen Mosher, Martin Morgan, Anton Nekrutenko, Brian D. O’Connor, Kevin Osborn, Benedict Paten, Candace Patterson, Frederick J. Tan, Casey Overby Taylor, Jennifer Vessio, Levi Waldron, Ting Wang, Kristin Wuichet, Alexander Baumann, Andrew Rula, Anton Kovalsy, Clare Bernard, Derek Caetano-Anollés, Geraldine A. Van der Auwera, Justin Canas, Kaan Yuksel, Kate Herman, M. Morgan Taylor, Marianie Simeon, Michael Baumann, Qi Wang, Robert Title, Ruchi Munshi, Sushma Chaluvadi, Valerie Reeves, William Disman, Salin Thomas, Allie Hajian, Elizabeth Kiernan, Namrata Gupta, Trish Vosburg, Ludwig Geistlinger, Marcel Ramos, Sehyun Oh, Dave Rogers, Frances McDade, Mim Hastie, Nitesh Turaga, Alexander Ostrovsky, Alexandru Mahmoud, Dannon Baker, Dave Clements, Katherine E.L. Cox, Keith Suderman, Nataliya Kucher, Sergey Golitsynskiy, Samantha Zarate, Sarah J. Wheelan, Kai Kammers, Ana Stevens, Carolyn Hutter, Christopher Wellington, Elena M. Ghanaim, Ken L. Wiley, Shurjo K. Sen, Valentina Di Francesco, Deni s Yuen, Brian Walsh, Luke Sargent, Vahid Jalili, John Chilton, Lori Shepherd, B.J. Stubbs, Ash O’Farrell, Benton A. Vizzier, Charles Overbeck, Charles Reid, David Charles Steinberg, Elizabeth A. Sheets, Julian Lucas, Lon Blauvelt, Louise Cabansay, Noah Warren, Brian Hannafious, Tim Harris, Radhika Reddy, Eric Torstenson, M. Katie Banasiewicz, Haley J. Abel, Jason Walker
Journal: Cell Genomics (2022)
Cardiology 1999
Authors: DH Spodick
Journal: Annals of Internal Medicine (2000)

Medical Writings: Book Notes1 August 2000Cardiology 1999David H. Spodick, MD, DScDavid H. Spodick, MD, DScSt. Vincent's Hospital, Worcester, Massachusetts. (Spodick)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-3-200008010-00026 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Willerson JT, Roberts WC, Rackley CE, Graham TP Jr, Mason DT, Parmley WW, eds. 784 pages. Armonk, NY: Futura; 1999. $125.00. ISBN 087993431X. Order phone 800-877-8761.Field of medicine: Cardiovascular medicine and surgery.Format: Hardcover book.Audience: Cardiologists, cardiovascular surgeons, internists, and trainees.Purpose: To provide authoritative analyses and summaries of important work in cardiology published from November 1997 to October 1998.Content: Ten sections cover “atherothrombosclerosis,” coronary artery disease, congestive heart failure, hypertension, valvular heart disease, arrhythmias, peripheral vascular disease, aortic inflammation, atherosclerotic aneurysms, cardiovascular disease in young persons, and transplantation. An appendix includes interviews with 10 leaders in ... Author, Article, and Disclosure InformationAffiliations: St. Vincent's Hospital, Worcester, Massachusetts. (Spodick) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 2000Volume 133, Issue 3Page: 244KeywordsCardiology and cardiovascular diseasesClinical epidemiologyMolecular epidemiologyPeripheral vascular diseaseSoftware toolsStable coronary artery diseaseSurgeonsSurgeryTransplantationVascular diseases ePublished: 15 August 2000 Issue Published: 1 August 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
DR. SAMUEL WARREN AND SURGICAL HISTORY.
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Books Received
Authors: Elisabeth Hertenstein, Nicola Thiel, Anne Katrin Külz, Dieter Riemann, Christoph Nissen, Marianne Lüking, Elisabeth Schramm, Chiara Baglioni, Kai Spiegelhalder, Fuschia M. Sirois, Danielle S. Molnar, Katharine A. Phillips, Joshua L. Roffman, Janet M. Witte, Alexandra S. Tanner, Sharmin Ghaznavi, Robert S. Abernethy, Laura D. Crain, Patricia U. Giulino, Ira Lable, Raymond A. Levy, Darin D. Dougherty, Karleyton C. Evans, Maurizio Fava, Richard Balon, David Veale, Martin Anson, Sarah Miles, Maria Pieta, Ana Costa, Nell Ellison, Anette Lampert, Jonas Tesarz, Anne-Katrin Volkert, Daniela Wesche, Beate Wild, Walter E. Haefeli, Michael Schwab, Sigal Zilcha-Mano, Jacques P. Barber, Raffaele Popolo, Paul H. Lysaker, Giampalo Salvatore, Antonella Montano, Luisa Buonocore, Laura Sirri, Antonella Imbimbo, Giancarlo Dimaggio, Frank Neuner, Thomas Elbert, Nadja Jacob, Anna Maedl, Susanne Schaal, Déborah Ducasse, Eric René, Séverine Béziat, Sébastien Guillaume, Philippe Courtet, Emilie Olié, Ueli Kramer, Stéphane Kolly, Franz Caspar, Pierre Marquet, Jean-Nicolas Despland, Yves de Roten, Christoph Flückiger, Satz Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle
Journal: Psychotherapy and Psychosomatics (2014)
Editorial board
Authors: James Field, Samuel Soskin, Beverly Hills, Garfield Duncan, Salman Azhar, Palo Alto, Hisham Barakat, George Bray, Jorge Calles-Escandon, Jose ´caro, M Charles, George Chrousos, Bernard Bethesda, St Davis, Leslie Louis, Frederick Degroot, Mario Derubertis, Atlanta Digirolamo, William Ga, Louis Duckworth, John Elsas, Kenneth Fain, San Feingold, Irving Francisco, Andrew Fox, New Frantz, Saul York, Henry Cleveland, New Ginsberg, Charles York, Abbas Glueck, Fredric Kitabchi, Stanford Kraemer, Nelly Mauras, James May, Donald Mcnamara, Glenn Mortimore, Maria New, New York, Caroline Pace, Michael Pagliassotti, William Denver, Alan Richmond, Los Robinson, Stanton Angeles, Peter Segal, Richard Stacpoole, Marc Durham, John Tucson
Journal: Metabolism (2003)
Walsh's Physician's Combined Call-Book and Tablet. Monthly Form. Thirtieth edition.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of abnormal myocardial flow reserve by myocardial perfusion echocardiography: Validation by positron emission tomography Lori B. Croft, Joseph A. Diamond, Samantha Buckley, Robert A. Phillips, Andrew Van Tosh, Steven Horowitz, Milena J. Henzlova, Josef Machac, Tamanna Nahar, Martin E. Goldman. Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, Beth Israel Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Duplication and Specialization of <i>NUDX1</i> in <i>Rosaceae</i> Led to Geraniol Production in Rose Petals
Authors: Corentin Conart, Nathanaelle Saclier, Fabrice Foucher, Clément Goubert, Aurélie Rius-Bony, Saretta N Paramita, Sandrine Moja, Tatiana Thouroude, Christophe Douady, Pulu Sun, Baptiste Nairaud, Denis Saint-Marcoux, Muriel Bahut, Julien Jeauffre, Laurence Hibrand Saint-Oyant, Robert C Schuurink, Jean-Louis Magnard, Benoît Boachon, Natalia Dudareva, Sylvie Baudino, Jean-Claude Caissard
Journal: Molecular Biology and Evolution (2022)

Nudix hydrolases are conserved enzymes ubiquitously present in all kingdoms of life. Recent research revealed that several Nudix hydrolases are involved in terpenoid metabolism in plants. In modern roses, RhNUDX1 is responsible for formation of geraniol, a major compound of rose scent. Nevertheless, this compound is produced by monoterpene synthases in many geraniol-producing plants. As a consequence, this raised the question about the origin of RhNUDX1 function and the NUDX1 gene evolution in Rosaceae, in wild roses or/and during the domestication process. Here, we showed that three distinct clades of NUDX1 emerged in the Rosoidae subfamily (Nudx1-1 to Nudx1-3 clades), and two subclades evolved in the Rosa genus (Nudx1-1a and Nudx1-1b subclades). We also showed that the Nudx1-1b subclade was more ancient than the Nudx1-1a subclade, and that the NUDX1-1a gene emerged by a trans-duplication of the more ancient NUDX1-1b gene. After the transposition, NUDX1-1a was cis-duplicated, leading to a gene dosage effect on the production of geraniol in different species. Furthermore, the NUDX1-1a appearance was accompanied by the evolution of its promoter, most likely from a Copia retrotransposon origin, leading to its petal-specific expression. Thus, our data strongly suggest that the unique function of NUDX1-1a in geraniol formation was evolved naturally in the genus Rosa before domestication.
Molecular precision medicine in pancreatic cancer: A single-center experience.
Authors: Anthony Tarabay, Antoine Hollebecque, Cristina Smolenschi, Leony Antoun, Caroline Klotz, Alina Fuerea, Audrey Perret, Claire Gouriou, Pascal Burtin, Hichem Belkhodja, Valérie Boige, David Malka, Michel Ducreux
Journal: Journal of Clinical Oncology (2022)

605 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of death by cancer worldwide. Mostly diagnosed with locally advanced or metastatic disease, patients lack for treatment options. Gene alterations (GAs) are frequently observed in PDAC, some of them considered as actionable with molecular targeted therapies (MTTs), with potential clinical benefits and improved outcomes. Methods: We conducted a retrospective analysis of all patients, aged ≥18 years, with histologically confirmed PDAC, who underwent tumor molecular profiling between 2010 and 2020 in our institution as part of personalized medicine trials. Overall survival was the primary study endpoint (minimal follow-up after molecular profiling, 6 months). Results: Of 115 eligible patients, molecular profiling was successful in 102 patients (89%). KRAS mutations were the most frequent GAs, mostly G12D. Actionable GAs were found in 29 patients (28%), involving mainly BRCA1/2 (5 [18%]), HER2 (5 [18%]), MTAP (5 [18%]), and FGFR (3 [11%]). Only 12 of these 29 patients (41%, or 10% of the whole population) could receive MTTs accordingly, with a median progression-free survival of 1.6 months. Median OS was 17 months in patients with actionable GAs treated with MTTs (n = 12 [11.8%]), 14 months in patients with actionable GAs not treated with MTTs (n = 17 [16.7%]), and 19 months in patients without actionable GAs treated with standard therapies (n = 73 [71.5%]; p = 0.26). The absence of liver metastases was associated with better OS (HR = 0.471, p = 0.01). The longest duration of response with MTTs was observed in patients with BRCA mutations treated with olaparib. Conclusions: Actionable GAs are found in more than the quarter of patients with advanced PDAC. Overall, targeting actionable GAs with MTTs was not associated with improved OS in this retrospective study. However, selected GA/MTT duets (e.g., BRCA mutations/olaparib) were associated with better outcome.
Galectin-9 expression and decreased survival in advanced biliary tract cancers.
Authors: Jessica M. Keilson, Amanda Ruggieri, Jacklyn Hammons, Helen X. Chen, Elad Sharon, Mark Yarchoan, Nilofer Saba Azad, Caroline Medin, Curtis Henry, Brian Robinson, Shishir K. Maithel, Gregory B. Lesinski
Journal: Journal of Clinical Oncology (2022)

465 Background: Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies often refractory to chemotherapeutic or targeted therapies, carrying an overall poor prognosis and high mortality. Identifying prognostic biomarkers and effective therapeutic targets for this disease therefore remains a high priority. T-cell immunoglobulin mucin domain-containing protein 3 (TIM-3), a negative regulatory immune checkpoint receptor, is known to induce immune tolerance and inhibit T-cell antitumor immunity. Its ligand, galectin-9 (Gal-9), has been shown to play a paradoxical role in tumorigenesis in a number of disease states. However, the role of Gal-9 in the setting of BTCs is not completely understood. Methods: We examined expression patterns of total cellular Gal-9 and TIM-3 in a panel of human BTC cell lines with diverse molecular profiles via immunoblot. Soluble Gal-9 (sGal-9) was measured by enzyme-linked immunoassay (ELISA). Tetrazolium-based MTT assay was utilized to evaluate cell viability following Ab-mediated Gal-9 neutralization. Pre-treatment peripheral blood was obtained from patients with metastatic BTCs enrolled in a randomized phase II clinical trial (NCI10139) and sGal-9 levels were measured. ROC curve analysis was employed to identify an optimal concentration cut-point value. Kaplan-Meier models were used to assess the association between sGal-9 levels and overall survival. Results: Human BTC cells demonstrate detectable and differential expression levels of total Gal-9 and TIM-3 proteins in vitro, with greater expression among intrahepatic cell lines (HUCCT-1, HUH28, SNU478). TIM-3 expression was not detected among extrahepatic (MzChA-1) and gallbladder cancer (WITT) cell lines. sGal-9 is secreted at variable levels between cell lines and its neutralization does not affect viability. Pre-treatment peripheral blood was obtained from 73 patients with metastatic BTCs (53% (n = 39) intrahepatic cholangiocarcinoma, 22% (n = 16) extrahepatic cholangiocarcinoma, 25% (n = 18) gallbladder cancer). There was no significant difference in sGal-9 levels between disease sites (p = 0.08). Patients were dichotomized by low and high sGal-9 levels. High baseline plasma levels of sGal-9 were associated with worse overall survival among patients with advanced BTCs (p = 0.03). Conclusions: Biliary tract cancer cells differentially express galectin-9 and its ligand, TIM-3, in vitro. Higher plasma levels of soluble galectin-9 are associated with worse overall survival, suggesting galectin-9 expression may be related to a more aggressive disease state. Additional work is needed to better inform the mechanistic role of the galectin-9/TIM-3 axis on disease progression and how best to leverage this pathway as a therapeutic target in the management of biliary tract cancers.
Setting sights and giving thanks
Authors: None The Lancet Rheumatology
Journal: The Lancet Rheumatology (2020)

This issue of The Lancet Rheumatology marks our first anniversary of publication, an occasion on which we are tempted to look back and celebrate the successes and achievements of the journal's inaugural year. But we shall resist this urge in favour of looking forward. In many ways, the situation for patients with rheumatic and musculoskeletal diseases is potentially worse today than it was a year ago. There is much work to be done.
Abstract P120: Relationship of Lipoproteins With Cardiovascular Disease in Persons With Chronic Kidney Disease
Authors: Archna Bajaj, Dawei Xie, Esteban Cedillo-Couvert, Jeanne Charleston, Jing Chen, Rajat Deo, Harold I Feldman, Alan S Go, Jiang He, Edward Horwitz, Radhakrishna R Kallem, Mahboob Rahman, Matthew R Weir, Amanda H Anderson, Daniel J Rader
Journal: Circulation (2017)

Introduction: Chronic kidney disease (CKD) is associated with dyslipidemia (particularly elevated triglycerides [TG] and reduced HDL-cholesterol [HDL-C]) and increased risk of atherosclerotic cardiovascular disease (CVD). However, the association between lipoprotein measures and CVD events in CKD is not well defined. Hypothesis: We hypothesize that high TG and low HDL-C are associated with increased risk for CVD (myocardial infarction [MI] and ischemic stroke) in CKD. Methods: The Chronic Renal Insufficiency Cohort (CRIC) is a prospective study of adults with CKD. We compared tertiles of TG, total cholesterol (TC), VLDL-cholesterol (VLDL-C), LDL-cholesterol (LDL-C), HDL-C, apolipoprotein B (apoB), and apolipoprotein A-I (apoA-I) with risk for MI and ischemic stroke using Fine and Gray methods with death as a competing risk. The lowest tertile was used as the reference category except for HDL-C and apoA-I, in which the highest tertile was used. In secondary analyses, we excluded participants with previous MI or stroke. Results: Among 3811 participants (55% men, 42% Caucasian) with mean age 57.7±11.0 years, 351 had an MI, 132 had an ischemic stroke, and 963 died over a median follow-up of 7.9 years. After adjusting for potential confounders, the hazard ratio (HR, 95% CI) for CVD was 1.04 (0.80-1.34) for high LDL-C, 1.31 (1.01-1.69) for high TG, 1.33 (1.04-1.70) for high VLDL-C, 1.30 (1.01-1.68) for high apoB, 1.65 (1.25-2.17) for low HDL-C, and 1.31 (1.01-1.70) for low apoA-I. In secondary analyses of 2751 participants with no CVD history, high TG (HR 1.46, 1.02-2.10), high VLDL-C (HR 1.56, 1.08-2.25), low HDL-C (HR 2.11, 1.40-3.16) and low apoA-I (HR 2.28, 1.54-3.37) were significantly associated with incident CVD. Conclusions: While high LDL-C is associated with increased CVD risk in the general population, we found no such association in CKD. Instead, high TG, high VLDL-C, low HDL-C and low apoA-I levels show strong associations with increased CVD risk and incident CVD events in CKD.
Some Medical Humorists
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal